Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Código QR

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Aline David-Silva,1 João Victor Esteves,1 Mychel Raony PT Morais,2 Helayne Soares Freitas,1 Telma Maria Zorn,2 Maria Lucia Correa-Giannella,3 Ubiratan Fabres Machado1 1Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, S&atil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Correa-Giannella ML, Machado UF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glut2 pepck g6pase phlorizin nash. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/af11b8b17fb8447cb14954ee70da7c4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Is cancer incidence modified by SGLT2 inhibitors?
por: Lev M. Berstein
Publicado: (2019)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser RF, et al.
Publicado: (2013)

Análisis de las redes de distribución de balón en fútbol: pases de juego y pases de adaptación
por: Isidro Maya Jariego, et al.
Publicado: (2013)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: David Bobrowski, et al.
Publicado: (2021)

GLP-1, SGLT-2, new devices for interventional cardiologists
por: Çetin Erol
Publicado: (2021)

Glucose and other hexoses transporters in marine invertebrates: A mini review
por: Martínez-Quintana,José Alfredo, et al.
Publicado: (2012)

Cross-cultural adaptation and validation of the Arabic version of the Physical Activity Scale for the Elderly among community-dwelling older adults in Saudi Arabia
por: Alqarni AM, et al.
Publicado: (2018)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Aurélie Pahud de Mortanges, et al.
Publicado: (2021)

GLUT1, GLUT3 Expression and 18FDG-PET/CT in Human Malignant Melanoma: What Relationship Exists? New Insights and Perspectives
por: Gerardo Cazzato, et al.
Publicado: (2021)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
por: Vladimir V Salukhov, et al.
Publicado: (2021)

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
por: Elisa Vergari, et al.
Publicado: (2019)

SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
por: Fateen Ata, et al.
Publicado: (2021)

Effects of SGLT-2 inhibitor on myocardial fibrosis and left ventricular reverse remodeling
por: Dipak Katare, et al.
Publicado: (2021)

Glucose transporters: expression, regulation and cancer
por: MEDINA,RODOLFO A., et al.
Publicado: (2002)

Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
por: Severin Schricker, et al.
Publicado: (2021)

Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
por: Rachel J. Perry, et al.
Publicado: (2019)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021)

Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
por: Braha A, et al.
Publicado: (2019)

Motor and Non-motor Symptoms Associated With Exercise Behavior in Parkinson's Disease Patients: Factors Differ Between Patients With and Without Postural Instability
por: Joomee Song, et al.
Publicado: (2021)

Antihyperglycaemia and related gene expressions of aqueous extract of Gongronema latifolium leaf in alloxan-induced diabetic rats
por: Basiru O. Ajiboye, et al.
Publicado: (2019)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert J
Publicado: (2015)

Chrysin ameliorates STZ-induced diabetes in rats: possible impact of modulation of TLR4/NF-κβ pathway
por: Abeer Salama, et al.
Publicado: (2022)

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
por: Ji-Yeon Lee, et al.
Publicado: (2021)

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
por: Taichi Sugizaki, et al.
Publicado: (2017)

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
por: Kumiko Shiba, et al.
Publicado: (2018)

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition
por: Wai-Lung Ng, et al.
Publicado: (2017)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Hyue Mee Kim, et al.
Publicado: (2021)

A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
por: Junichi Mukai, et al.
Publicado: (2021)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
por: So Ra Kim, et al.
Publicado: (2020)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
por: Mustafa Kılıçkap, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
por: Wen-Hsuan Tsai, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Jiali Liu, et al.
Publicado: (2017)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Study of Cytochrome P450 2E1 and its allele Variants in Liver Injury of Nondiabetic, Nonalcoholic Steatohepatitis Obese Women
por: VARELA,NELSON M, et al.
Publicado: (2008)

Investigation of the Role of Glucose Decorated Chitosan and PLGA Nanoparticles as Blocking Agents to Glucose Transporters of Tumor Cells
por: Abolhasani A, et al.
Publicado: (2019)